Weidong Han

39PUBLICATIONS
41CO-AUTHORS
Innate immunityCancer therapy (excl. chemotherapy and radiation therapy)Chemical engineering designMolecular targetsCheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Oct 22, 2026
Histone deacetylase inhibition induces an antitumor IRF8-dependent trained immunity-like status in macrophages.

|May 08, 2026
Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent-programmed CAR T cells.

|Apr 27, 2026
Inhibition of glycosphingolipid synthesis overcomes the steric hindrance of CD30 N-glycans to augment CD30-targeted immunotherapeutic efficacy.

|Apr 15, 2026
Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial.

|Mar 18, 2026
DUSP6 ablation restores CAR T-cell fitness impaired by tumor CD58 loss through invigoration of AP-1 signaling.

Xinran Ma, Yang Zhang, Yao Wang

|Mar 10, 2026
Five-Year Follow-Up: Tandem CD19/CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non-Hodgkin Lymphoma.

Fuxin Han, Yadi Zhong, Chuan Tong

Pageof 7

Frequent Collaborators

10 joint publications

Yao Wang

8 joint publications

Zhiqiang Wu

4 joint publications

Jing Nie

3 joint publications

Xin Lin